Metoclopramide and Risk of Pheochromocytoma Crisis: A Causality Assessment Using Literature and VigiBase Data Authors: Merhawi Bahta, Abraham Dawit, Million Okubazghi, Mulugeta Russom Published: 2026 ABSTRACT IntroductionThe association between metoclopramide and pheochromocytoma crisis has been documented in literature. However, evidence has primarily relied on case reports and small-scale experimental studies rather than rigorous causal assessments. Therefore, this study aimed to assess the causal relationship between metoclopramide use and the occurrence of pheochromocytoma crisis by analyzing data from the literature and World Health Organization (WHO) global pharmacovigilance database.MethodsThis study was a descriptive analysis and causality assessment of metoclopramide and pheochromocytoma crisis. Data were retrieved from published literature and the WHO global pharmacovigilance database (VigiBase) on February 13, 2025. In addition to the causality results extracted from VigiBase, causality assessment at the individual level for published case reports was conducted using the Naranjo Adverse Drug Reaction Probability Scale. Causality assessment at the population level was conducted using the Austin Bradford-Hill causality assessment framework.ResultsA total of 62 de-duplicate cases were found in VigiBase and the literature. Almost all cases were classified as serious with 12 fatalities. In many instances, the drug-induced crisis served as the first clinical indication of an undiagnosed (occult) tumor. A causality assessment using the Naranjo algorithm conducted by the current authors classified the 18 published cases as “probable” (13) and “possible” (5). In VigiBase, causality assessment at the individual level was reported for 10 cases, with possible (6), probable (2), and reasonable possibilities (2). The results of the causality assessment at the population level using Hill’s criteria revealed compelling evidence across all nine criteria.ConclusionA reasonable causal relationship exists between metoclopramide and pheochromocytoma crisis, supporting its contraindication in patients with known or suspected pheochromocytoma.Clinicians should monitor patients, consider underlying pheochromocytoma, and be aware of this risk. Further international case-control studies are recommended to confirm this causal association. Introduction Metoclopramide is a commonly used antiemetic and prokinetic agent that is generally well tolerated, although it is known for its adverse effects, such as extrapyramidal reactions and tardive dyskinesia.1–4 Of particular clinical concern is its association with pheochromocytoma crisis in patients with a history of pheochromocytoma.5 Pheochromocytoma crisis, although rare with an annual incidence rate of 0.8 cases per 100,000 person-years,6,7 is a life-threatening condition. It occurs when a pheochromocytoma, a type of neuroendocrine tumor, abruptly releases excessive amounts of catecholamines (epinephrine and norepinephrine).8 This sudden surge can lead to hypertensive crises, hemodynamic instability, neurological symptoms, cardiomyopathy, and/or acute pulmonary edema, which can ultimately lead to multiorgan failure and significant mortality if left untreated.8 Pheochromocytoma crisis can present spontaneously if there is necrosis or hemorrhage of the tumor itself or if there is any source of external pressure on the tumor, such as trauma, vigorous exercise, pregnancy, and surgery.9,10 Metoclopramide and other drugs including various anesthetic agents, glucocorticoids, amisulpride, tiapride, droperidol, β-blockers, tricyclic anti-depressants, MAO inhibitors, opiates, methyldopa, nicotine, cocaine and certain radio contrast media,5,10–14 have also been associated with pheochromocytoma crisis. Metoclopramide increases catecholamine levels in patients with other forms of hypertension.15 Additionally, the existing literature includes several documented case reports16–30 and small-scale experimental studies22,25,31 describing pheochromocytoma crisis/hypertensive crisis associated with metoclopramide in individuals with pheochromocytoma, while one study32 indicated no association. Consequently, metoclopramide is contraindicated in patients with known or suspected pheochromocytoma, or other catecholamine-releasing paragangliomas.1–3 Despite, metoclopramide has been implicated in triggering such crises; the evidence remains limited and largely based on case reports, lacking large-scale epidemiological data directly demonstrating a causal link. This is primarily because of the rarity of pheochromocytoma resulting in limited number of pheochromocytoma crisis cases, which makes large-scale studies with specific triggers challenging. Given the widespread clinical use of metoclopramide and availability of limited evidence on the association, a structured causality assessment is therefore warranted to further characterize and strengthen the association for pharmacovigilance and clinical practice. Therefore, this study aimed to assess the causal relationship between metoclopramide use and the occurrence of pheochromocytoma crises in patients with pheochromocytoma using the Naranjo scale and the Austin Bradford Hill Criteria. This study performs signal verification using data from the World Health Organization (WHO) global pharmacovigilance database and relevant medical literature. Methods Study Design This study employed a descriptive analysis and causality assessment design to investigate the potential association between metoclopramide use and the occurrence of pheochromocytoma crisis. Data Sources Data were systematically retrieved from two primary sources: the WHO global pharmacovigilance database (VigiBase)33 and the published literature. VigiBase is developed and maintained by the Uppsala monitoring centre on the behalf of the WHO. Access is restricted to national pharmacovigilance centers that are members of the WHO Programme for International Drug Monitoring. The database has been pooling safety data of medical products from different countries since 1968. It is the world’s largest pharmacovigilance database, compiling safety information from over 150 countries, and currently has over 40,445021 unique (de-duplicated) individual case safety reports (ICSRs) as of February 13, 2025. Exposure and Outcome Definition The exposure of interest was metoclopramide- or metoclopramide-containing medications in any dosage form, regardless of the dose, frequency, or duration. Excess catecholamine release from pheochromocytoma tumors triggered by metoclopramide can lead to life-threatening pheochromocytoma crisis. Clinical manifestations depend on the catecholamine profile of the tumor; most tumors secrete more norepinephrine, resulting in severe hypertension, whereas excess epinephrine can cause severe hypotension.10 Therefore, this study’s outcome measure focused on the reported pheochromocytoma crisis following metoclopramide use. Data Retrieval Approach in the Global Pharmacovigilance Database, VigiBase Data were extracted from VigiBase using VigiLyze, an analysis tool developed by the Uppsala Monitoring Center on behalf of WHO.33 The search was made on February 13, 2025, using “metoclopramide” as the active ingredient or drug substance, along with the following MedDRA (Medical Dictionary for Regulatory Activities) reaction terms: Phaeochromocytoma crisis (PT), Phaeochromocytoma (PT), and Hypertensive crisis (PT). This approach aimed to identify all globally reported cases of pheochromocytoma crisis associated with metoclopramide. Widely recognized in the medical community, these terms ensure specificity in data retrieval and enhance the relevance of findings. The term “Hypertensive Crisis” encompasses a broader range of related cases, facilitating a more comprehensive search. Including “pheochromocytoma” further improves the specificity by directly linking the search to the condition itself, making it easier to identify relevant cases through co-reported reactions or clinical manifestations. Data Retrieval from Literature PubMed and Google Scholar were used to search for published case reports and literature on metoclopramide and pheochromocytoma crises on February 13, 2025. The search strategy utilized a combination of keywords: “metoclopramide”, “pheochromocytoma”, “pheochromocytoma crisis”, and “hypertensive crisis.” The search terms used in the PubMed advanced and Google scholar was (metoclopramide) AND (pheochromocytoma OR pheochromocytoma crisis OR hypertensive crisis). The search was limited to articles published in the English language publications; therefore, non-English studies may exist but were not included. Furthermore, a Summary of Product Characteristics (SmPCs) and equivalent regulatory product information of various manufacturers approved by the United States Food and Drug Administration,2 the Medicines and Healthcare Products Regulatory Authority of the UK,3 and Australia Therapeutic Goods Administration1 were reviewed for documentation and labeling. Case Selection and De-Duplication All identified articles and VigiBase reports describing cases of pheochromocytoma crisis associated with metoclopramide use were reviewed for duplications. The Uppsala Monitoring Centre’s VigiMatch34 was used to remove duplicate safety reports from the analysis by setting the VigiBase to “de-duplicate”. VigiMatch considers factors such as patient age, sex, reported medications, adverse drug reactions, and country of origin. Additionally, manual checks of the VigiBase cases for duplication were conducted by two authors and potential duplicates were removed if they were discovered. Furthermore, duplicates across both VigiBase and published literature were meticulously identified and removed to ensure that each reported case was unique. Therefore, only unique cases were included in the final analyses. Data Analysis and Causality Assessment Data from VigiBase and published case reports were exported to an Excel worksheet 2019 for further descriptive analysis. The collected dataset included reaction outcomes, seriousness, reason for seriousness, time to onset of pheochromocytoma crisis, dechallenge and rechallenge information, co-reported drugs and reactions, clinical and diagnostic findings, patient history, patient demographic features, dose, reporting countries, completeness score, and other pertinent information. The information component (IC025), proportional reporting ratio (PRR025), and reporting odds ratio (ROR025) values were retrieved from VigiBase. These values measure reporting disproportionality in the association between specific drugs and adverse reactions. A positive IC value, PRR025 >1, and ROR025 >1 indicates that a particular drug adverse reaction pair has been reported more often than expected, based on all the reports in VigiBase suggesting a potential safety signal.35–37 These cut-offs reflect the minimum threshold at which reporting exceeds expectation. Additional data required for causality assessment were retrieved from the published literature. In addition to the causality results extracted from VigiBase, causality assessment at the individual level of the published case reports was conducted using the standard Naranjo Adverse Drug Reaction Probability Scale.38 Finally, relevant information obtained from various data sources was carefully organized and aggregated using the Austin Bradford-Hill causality assessment framework to investigate the causal relationship between metoclopramide and the pheochromocytoma crisis at the population level.39 Accordingly, potential causal relationship was systematically assessed using the nine Hill’s criteria. The level of evidence that supports the causal relationship or otherwise provides an alternative explanation was finally weighted based on the authors’ consensus. Results Reports in the WHO Global Pharmacovigilance Database, VigiBase Data retrieved on February 13, 2025, yielded 49 valid cases after de-duplication, which was performed first using the VigiLyze automated de-duplication function and subsequently through manual review (Figure 1). These cases were reported to the VigiBase between 1996 and 2024. Details of 44 of the 49 cases are summarized in Table 1, while the remaining five cases are included in Table 2 (published cases), as they were also found to be published in the literature. Table 1Details of Pheochromocytoma Crisis Cases Associated with Metoclopramide Use, Retrieved from VigiBase (N=44 Cases)CharacteristicsNumber%SexMale1329.5Female3170.5SeriousnessYes3681.8No36.8Unknown511.4Reasons for seriousness*Death920.5Caused/prolonged hospitalization2250.0Other medically important condition2045.5Life threatening1329.5Disabling/Incapacitating24.5ReportersPhysician2045.5Pharmacist36.8Other Health Professional1329.5Lawyer12.3Consumer/Non-Health Professional511.4Unknown24.5OutcomeRecovered1738.6Died920.5Recovering613.6Unknown1227.3Reporting countriesUnited States of America1329.5Japan1227.3Italy49.1France36.8United Kingdom36.8Germany24.5Mexico24.5Singapore24.5Austria12.3Australia12.3Malaysia12.3Dechallenge informationPositive613.6Unknown3886.4Rechallenge informationPositive00.0Unknown44100Suspected drugsMetoclopramide as sole suspected drug3170.5Metoclopramide with concomitant suspected drugs1329.5Drugs administeredMetoclopramide administered alone1943.2Metoclopramide administered with concomitant medications2546.8Causality resultPossible613.6Probable24.5Reasonable possibilities24.5Unknown3477.3Completeness score>0.8613.6Between 0.5 and 0.8715.9<0.53170.5Time to reaction onset0 day36.81 day12.32 days12.330 days12.360 days12.3Unknown3784.1Dose10mg1738.630mg36.8Unknown2454.5Route of administrationIntravenous1227.3Oral36.8Intramuscular12.3Unknown route2863.6Statistical associationPreferred termsInformation component (IC025)PRR025ROR025All three terms1.02.12.1Phaeochromocytoma crisis4.582.4127.0Phaeochromocytoma2.810.717.1Hypertensive crisis−1.50.40.7Note: * Multiple reasons are possible.Abbreviations: IC, Information component; n, Number; PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio; STD, Standard Deviation. Table 2Summary of Published Cases of Metoclopramide-Associated Pheochromocytoma Crisis and Their Individual Case Causality AssessmentsCase ReportAge (Years)/SexMetoclopramideRegimenMetoclopramideIndicationConcomitant MedicinesTime-to-Reaction OnsetOutcomeDechallenge/ Rechallenge; Other Experimental EvidencesAlternative Explanations Ruled out/inCausality(Naranjo)Yuhua Xie et al, 20231646/FUnknownNausea and vomitingTropisetron3-4 hoursRecoveredUnknown/ UnknownIntra uterine device (IUD) removal procedure which can cause the crisis was documented, but its causative role was excluded. No other alternative causes were identified.ProbableJacob Lloyd et al, 20221741/FIVMigraine/ Severe headacheAnti hypertensive not specifiedShortly thereafterRecoveredUnknown/ UnknownNo alternative causes were identified.ProbableLeng SLS et al, 20222758/FIVVomitingNAFollowing the administrationRecoveredUnknown/ UnknownNo alternative causes were identified.ProbableAurelio Negro et al, 20212133/F10 mg daily for 2 days followed by 10 mg bid for 5 daysNausea and dyspepsiaAlpha methyldopa; Nifedipine extended release; insulin therapy7 daysRecoveredUnknown/UnknownThe pre-eclampsia/eclampsia related hypertension and beta blocker usage were documented, but their causative role was ruled out. However, pregnancy was documented and its causative role in the crisis neither confirmed nor excluded.PossibleJames B Leonard et al, 20181836/FUnknownNauseaOral acetaminophen1 hourDiedUnknown/UnknownNo alternative causes were identified.ProbableMichelle Dawson et al, 20172036/F10 mg, stat, IVNausea and vomitingNAImmediateRecoveredUnknown/UnknownNo alternative causes were identified.ProbableSumit Patel et al, 20173036/FUnknownNauseaDiphenhydramine and Methylprednisolone1 hourRecoveredUnknown/UnknownDiphenhydramine and methylprednisolone were documented but their causative role in the crisis neither confirmed nor excluded.PossibleRosanne Sheinberg et al, 20121945/FUnknownNauseaNAAfter metoclopramide administrationDiedUnknown/UnknownTakotsubo cardiomyopathy was documented, but its causative role was excluded; no other alternative causes were identified.ProbableJohann Guillemot et al, 20092246/F10 mg, POVomitingNA30 minutesRecoveredUnknown/UnknownNo alternative causes were identified.ProbableSarah Frankton et al, 20092447/M10 mg, IMNauseaGlucose (50% and 5%); HydrocortisoneImmediateDiedUnknown/UnknownHydrocortisone, hypoglycemia and abdominal pain were present but their causative role in the crisis neither confirmed nor excluded.PossibleM K Leow et al, 20052330/M10 mg IMVomitingNAImmediateRecoveredUnknown/UnknownAbdominal pain was documented, but its causative role in the crisis neither confirmed nor excluded.Possible27/M10 mg, IV and 2nd dose of 10 mgVomitingNAAbout 25 minutes for the first dose and immediate for the second doseRecoveredUnknown/Unknown; Blood pressure increased after the second dose, even though the rise following the first dose resolved spontaneously.Abdominal pain was documented, but its causative role was excluded; no other alternative causes were identified.Probable61/F10 mgVomitingNA30 minRecoveredUnknown/UnknownHypoglycaemia was documented, but its causative role was excluded; no other alternative causes were identified.ProbableMasayoshi Abe et.al., 19842545/F10 mg, IVTest/ProvocationInsulin, PhentolamineAbout 3 minutesRecoveredUnknown/Positive; There was no hypertensive crisis in the two other persons used as controlsNo alternative causes were identified.ProbableY. Takai et al, 19972637/F10 mg, IV (drip infusion)Nausea and vomiting during pregnancyNASeveral hours after metoclopramide infusionRecoveredUnknown/UnknownPregnancy was documented, but its causative role in the crisis neither confirmed nor excluded.PossibleAgabiti-Rosei et al, 19772935/M10 mg, IVTest/ProvocationNA2 minutesRecoveredUnknown/Unknown; There was no change in blood pressure or plasma catecholamine levels in four other individuals without pheochromocytomaNo alternative causes were identified.Probable43/F10 mg, IVTest/ProvocationNA2 minutesUnknownUnknown/UnknownNo alternative cause was identified.ProbablePlouin et al, 197628Not reported10 mg, IVNauseaSodium nitroprusside2-3 minutesRecoveredUnknown/UnknownArteriography was documented, but its causative role was excluded; no other alternative causes were identified.ProbableAbbreviations: NA, Not Available; IV: Intravenous. Figure 1Flow diagram showing case identification and validation process for cases of pheochromocytoma crisis associated with metoclopramide.A flowchart detailing the case identification process for metoclopramide and pheochromocytoma crisis. It begins with the total number of Individual Case Safety Reports in VigiBase under the 'Full' duplicate scope, totaling 41,262,172. From these, 81,420 reports are related to metoclopramide. Of these, 78 are related to metoclopramide and pheochromocytoma crisis. After excluding 29 duplicate cases using automated vigiLyze and manual checking, 49 valid cases remain. An additional 18 cases are added from published literature. Five duplicate cases are removed as they were found in both literature and the global database. The total number of valid cases included in the study is 62.Flowchart for identifying metoclopramide and pheochromocytoma crisis, with data filtering and validation. Table 1Details of Pheochromocytoma Crisis Cases Associated with Metoclopramide Use, Retrieved from VigiBase (N=44 Cases)CharacteristicsNumber%SexMale1329.5Female3170.5SeriousnessYes3681.8No36.8Unknown511.4Reasons for seriousness*Death920.5Caused/prolonged hospitalization2250.0Other medically important condition2045.5Life threatening1329.5Disabling/Incapacitating24.5ReportersPhysician2045.5Pharmacist36.8Other Health Professional1329.5Lawyer12.3Consumer/Non-Health Professional511.4Unknown24.5OutcomeRecovered1738.6Died920.5Recovering613.6Unknown1227.3Reporting countriesUnited States of America1329.5Japan1227.3Italy49.1France36.8United Kingdom36.8Germany24.5Mexico24.5Singapore24.5Austria12.3Australia12.3Malaysia12.3Dechallenge informationPositive613.6Unknown3886.4Rechallenge informationPositive00.0Unknown44100Suspected drugsMetoclopramide as sole suspected drug3170.5Metoclopramide with concomitant suspected drugs1329.5Drugs administeredMetoclopramide administered alone1943.2Metoclopramide administered with concomitant medications2546.8Causality resultPossible613.6Probable24.5Reasonable possibilities24.5Unknown3477.3Completeness score>0.8613.6Between 0.5 and 0.8715.9<0.53170.5Time to reaction onset0 day36.81 day12.32 days12.330 days12.360 days12.3Unknown3784.1Dose10mg1738.630mg36.8Unknown2454.5Route of administrationIntravenous1227.3Oral36.8Intramuscular12.3Unknown route2863.6Statistical associationPreferred termsInformation component (IC025)PRR025ROR025All three terms1.02.12.1Phaeochromocytoma crisis4.582.4127.0Phaeochromocytoma2.810.717.1Hypertensive crisis−1.50.40.7Note: * Multiple reasons are possible.Abbreviations: IC, Information component; n, Number; PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio; STD, Standard Deviation. Details of Pheochromocytoma Crisis Cases Associated with Metoclopramide Use, Retrieved from VigiBase (N=44 Cases) Note: * Multiple reasons are possible. Abbreviations: IC, Information component; n, Number; PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio; STD, Standard Deviation. Table 2Summary of Published Cases of Metoclopramide-Associated Pheochromocytoma Crisis and Their Individual Case Causality AssessmentsCase ReportAge (Years)/SexMetoclopramideRegimenMetoclopramideIndicationConcomitant MedicinesTime-to-Reaction OnsetOutcomeDechallenge/ Rechallenge; Other Experimental EvidencesAlternative Explanations Ruled out/inCausality(Naranjo)Yuhua Xie et al, 20231646/FUnknownNausea and vomitingTropisetron3-4 hoursRecoveredUnknown/ UnknownIntra uterine device (IUD) removal procedure which can cause the crisis was documented, but its causative role was excluded. No other alternative causes were identified.ProbableJacob Lloyd et al, 20221741/FIVMigraine/ Severe headacheAnti hypertensive not specifiedShortly thereafterRecoveredUnknown/ UnknownNo alternative causes were identified.ProbableLeng SLS et al, 20222758/FIVVomitingNAFollowing the administrationRecoveredUnknown/ UnknownNo alternative causes were identified.ProbableAurelio Negro et al, 20212133/F10 mg daily for 2 days followed by 10 mg bid for 5 daysNausea and dyspepsiaAlpha methyldopa; Nifedipine extended release; insulin therapy7 daysRecoveredUnknown/UnknownThe pre-eclampsia/eclampsia related hypertension and beta blocker usage were documented, but their causative role was ruled out. However, pregnancy was documented and its causative role in the crisis neither confirmed nor excluded.PossibleJames B Leonard et al, 20181836/FUnknownNauseaOral acetaminophen1 hourDiedUnknown/UnknownNo alternative causes were identified.ProbableMichelle Dawson et al, 20172036/F10 mg, stat, IVNausea and vomitingNAImmediateRecoveredUnknown/UnknownNo alternative causes were identified.ProbableSumit Patel et al, 20173036/FUnknownNauseaDiphenhydramine and Methylprednisolone1 hourRecoveredUnknown/UnknownDiphenhydramine and methylprednisolone were documented but their causative role in the crisis neither confirmed nor excluded.PossibleRosanne Sheinberg et al, 20121945/FUnknownNauseaNAAfter metoclopramide administrationDiedUnknown/UnknownTakotsubo cardiomyopathy was documented, but its causative role was excluded; no other alternative causes were identified.ProbableJohann Guillemot et al, 20092246/F10 mg, POVomitingNA30 minutesRecoveredUnknown/UnknownNo alternative causes were identified.ProbableSarah Frankton et al, 20092447/M10 mg, IMNauseaGlucose (50% and 5%); HydrocortisoneImmediateDiedUnknown/UnknownHydrocortisone, hypoglycemia and abdominal pain were present but their causative role in the crisis neither confirmed nor excluded.PossibleM K Leow et al, 20052330/M10 mg IMVomitingNAImmediateRecoveredUnknown/UnknownAbdominal pain was documented, but its causative role in the crisis neither confirmed nor excluded.Possible27/M10 mg, IV and 2nd dose of 10 mgVomitingNAAbout 25 minutes for the first dose and immediate for the second doseRecoveredUnknown/Unknown; Blood pressure increased after the second dose, even though the rise following the first dose resolved spontaneously.Abdominal pain was documented, but its causative role was excluded; no other alternative causes were identified.Probable61/F10 mgVomitingNA30 minRecoveredUnknown/UnknownHypoglycaemia was documented, but its causative role was excluded; no other alternative causes were identified.ProbableMasayoshi Abe et.al., 19842545/F10 mg, IVTest/ProvocationInsulin, PhentolamineAbout 3 minutesRecoveredUnknown/Positive; There was no hypertensive crisis in the two other persons used as controlsNo alternative causes were identified.ProbableY. Takai et al, 19972637/F10 mg, IV (drip infusion)Nausea and vomiting during pregnancyNASeveral hours after metoclopramide infusionRecoveredUnknown/UnknownPregnancy was documented, but its causative role in the crisis neither confirmed nor excluded.PossibleAgabiti-Rosei et al, 19772935/M10 mg, IVTest/ProvocationNA2 minutesRecoveredUnknown/Unknown; There was no change in blood pressure or plasma catecholamine levels in four other individuals without pheochromocytomaNo alternative causes were identified.Probable43/F10 mg, IVTest/ProvocationNA2 minutesUnknownUnknown/UnknownNo alternative cause was identified.ProbablePlouin et al, 197628Not reported10 mg, IVNauseaSodium nitroprusside2-3 minutesRecoveredUnknown/UnknownArteriography was documented, but its causative role was excluded; no other alternative causes were identified.ProbableAbbreviations: NA, Not Available; IV: Intravenous. Summary of Published Cases of Metoclopramide-Associated Pheochromocytoma Crisis and Their Individual Case Causality Assessments Abbreviations: NA, Not Available; IV: Intravenous. Flow diagram showing case identification and validation process for cases of pheochromocytoma crisis associated with metoclopramide. The 44 valid cases were submitted to VigiBase from 11 countries, predominantly the USA (29.5%) and Japan (27.3%) (Table 1). Most cases were reported by physicians (45.5%), followed by other health care professionals (29.5%). The reported PT terms included pheochromocytoma crisis, pheochromocytoma, and hypertensive crisis. The co-reported terms with pheochromocytoma included organ failure and hypertension, while only pheochromocytoma as a reaction was reported in three cases. The majority of the cases involved females (70.5%), with a mean age of 49.6 years (Standard Deviation= 18.6; Minimum= 6; Maximum= 80). A significant proportion (81.8%) of the cases were marked as serious and 20.5% were fatal. Outcomes varied, with 17 cases reported as recovered, six as recovering, 12 with unknown outcomes, and nine resulting in death. Time to reaction onset was documented in seven cases where three cases occurred within one day. In six cases, the reaction resolved when metoclopramide was withdrawn, while the rechallenge information was unknown in all cases. The completeness score of the ICSRs was less than 0.5 in 31 patients while only six cases were well documented (completeness score > 0.8). The dose was documented in only 20 cases, of which 17 patients were taking 10 mg at a time. The route of administration was specified in 16 patients, and metoclopramide was administered intravenously in 12 patients. Metoclopramide was identified as the sole suspected drug in 31 cases and was the only drug administered in 19 cases. From the quantitative analysis using VigiLyze, a strong statistical signal was observed for the association between metoclopramide and phaeochromocytoma crisis: IC025 = 4.5, PRR025=82.4, and ROR025= 127.0 (Table 1). A statistical signal was also observed when combining the terms “phaeochromocytoma crisis”, “phaeochromocytoma” and “hypertensive crisis” (Table 1). Frequently co-reported reactions include hypertension, multiple organ dysfunction syndrome, cardiogenic shock, acute respiratory distress syndrome, and acute hepatic failure, along with other serious conditions, such as metabolic acidosis, pulmonary edema, tachycardia, and acute kidney injury. Findings from Literature Initially, 54 articles in PubMed and 1,290 in Google Scholar were identified using the search criteria (metoclopramide) AND (pheochromocytoma OR pheochromocytoma crisis OR hypertensive crisis). From these, 15 relevant articles with eighteen unique cases were identified. The majority (13 cases) of the patients were females while four were male; in one case, sex was not reported. The mean age of the cases was 41.4 years (minimum= 29; maximum= 61 years; Standard Deviation = 8.9 years). Metoclopramide was administered primarily for symptoms of nausea and vomiting in 15 patients16–24,26–28,30 and as a provocation test for pheochromocytoma in three cases.25,29 The doses varied, with the predominant use of a stat dose of 10 mg administered intravenously in most cases. A summary of the data for each published case is presented in Table 2. Metoclopramide was the only medication administered to 10 of the 18 patients, whereas concomitant medications, such as tropisetron, methylprednisolone, hydrocortisone, and unspecified antihypertensives, were documented in eight patients (Table 2). The time to symptom onset ranged from immediate to a few minutes after metoclopramide administration in the majority of cases (Table 2). In addition, no pheochromocytoma crisis occurred when metoclopramide was administered following adrenalectomy in one case.25 There was also no change in blood pressure or plasma catecholamine levels in six other individuals used as controls in two studies in which metoclopramide was administered as a provocation test.25,29 Pheochromocytoma crisis was diagnosed clinically and biochemically through plasma and urinary catecholamines and was confirmed by radiological imaging and post-adrenalectomy histopathological tests in the majority of cases. Clinical manifestations varied widely and included tachycardia, hypertension, multiorgan failure (including acute respiratory failure), and altered consciousness, necessitating management strategies that involve invasive ventilation, renal replacement therapy, and pharmacological and surgical interventions. All cases were serious with two fatal outcomes (Table 2). In addition to case reports, several in vivo and in vitro experimental studies have revealed that metoclopramide can stimulate catecholamine release in patients with pheochromocytoma and isolated human pheochromocytoma cells22,25,29,31,40 with suggestive biological mechanisms and dose-response relationships.15,22,25,29,40 An association between pheochromocytoma and other pharmacologically similar drugs has also been reported.13,14,22,41 In a study by Kawabe et al, a significant pressor response to intravenous doses of 5 mg of metoclopramide was found only in 5 patients with pheochromocytoma, in contrast to the subjects with essential hypertension (12 patients) and normotension (9 patients) who tended to display slight depressor responses.31 Causality Assessment at Individual Case Level A causality assessment of the association between metoclopramide and pheochromocytoma crisis in each published case report was conducted by the authors using the Naranjo causality assessment tool.38 Accordingly, 13 cases were classified as “probably related”, and the remaining five cases were rated as possibly related to metoclopramide (Table 2). Furthermore, causality results were also reported in 10 cases from VigiBase, with possible, probable, and reasonable possibilities reported in 6, 2, and 2 cases, respectively (Table 1). According to the causality assessment of the published cases (Table 2), the probable cases were characterized by a clear temporal relationship between metoclopramide administration and the onset of pheochromocytoma crisis, often within minutes to hours, and by the absence of alternative explanations or explicit exclusion of competing causes. Possible cases typically involved known alternative triggers such as pregnancy, concomitant medications, and metabolic disturbances, which could not be definitively ruled out or confirmed as causal factors. Dechallenge and rechallenge data were generally unavailable or confounded by acute therapeutic interventions, reflecting the severity of the clinical presentations. In the controlled provocation study25 by Abe et al, a true positive rechallenge was identified when the crisis recurred upon the second administration of metoclopramide. Explicit objective evidence was available for all cases. Several Naranjo items, including dose–response relationship, placebo challenge, and drug concentration measurements, were uniformly scored as unknown due to the unavailability of data. Causality Assessment at Population Level The causal relationship between pheochromocytoma crisis and metoclopramide at the population level was assessed by analyzing data from VigiBase and the literature using the Austin Bradford Hill’s Criteria.39 The causality assessment results are presented in Table 3. Table 3Summary of Evidence: Hill’s Criteria for Causality AssessmentCriteriaSummary of EvidenceInterpretation1Strength of associationIn the global pharmacovigilance database, VigiBase, a robust statistical signal was observed for this association. For pheochromocytoma crisis specifically, an Information Component (IC025) value of 4.5, a Proportional Reporting Ratio (PRR025) of 82.4, and a Reporting Odds Ratio (ROR025) of 127.0 were reported.There is a strong statistical association between metoclopramide and pheochromocytoma crisis.2Consistency of the casesCases reported to VigiBase originated from 11 countries across five continents. Furthermore, 11 of the published cases showed reaction onset of immediate or within a few minutes, contributing to the consistency of the observed association.The association between metoclopramide and pheochromocytoma crisis demonstrates consistency across various reports.3Specificity of the associationMetoclopramide was identified as the sole suspected drug in 46 of all the cases, with 29 of them (10 published cases and 19 from VigiBase) involving metoclopramide as the only administered medication. In all (18) published cases, there was a clear diagnosis of pheochromocytoma crisis/hypertensive crisis and the underlying condition of pheochromocytoma. Additionally, no alternative causes were identified in 13 of the published cases, and in five of these, other alternatives were specifically ruled out (Table 2).The association appears specific in terms of the exposure and outcome of interest.4TemporalityIn all (n=62) of the cases pheochromocytoma crisis occurred following metoclopramide administration. Specifically, a plausible temporal relationship exists, as pheochromocytoma crisis developed immediately within a few minutes following metoclopramide administration in almost all the published cases.There is a plausible temporal relationship.5Dose-responserelationship/ biological gradientExperimental study has shown that administering graded concentrations of metoclopramide to pheochromocytoma cells induced a dose-dependent increase in norepinephrine and epinephrine secretion.22Evidence suggests a plausible dose-response relationship6Biological mechanism orPlausibilityResearches indicate that metoclopramide may induce catecholamine release through dopamine D2 receptor inhibition5,25 and/or activation of serotonin 5-HT4 receptors.22 Metoclopramide is also suggested to stimulate the release of biologically active vasopressin in humans.42There are proposed biological mechanisms suggestive of this association.7ExperimentTwo cases, in which metoclopramide was used as provocation test,25,29 confirmed the crisis onset within 2–3 minutes following IV administration and no effects were noted when metoclopramide was readministered after tumor removal.25 There was also no change in blood pressure or plasma catecholamine levels in six other individuals used as controls in these two studies.25,29 Another study by Kawabe et al reported a significant pressor response to intravenous metoclopramide only in patients with pheochromocytoma, whereas patients with essential hypertension and normotensive subjects showed mild depressor responses.31 Metoclopramide has also been shown to increase catecholamine release from isolated human pheochromocytomas but not from isolated rat adrenal glands used as control tissue.40 Tissue explants from pheochromocytomas demonstrated metoclopramide’s stimulating effect on catecholamine release by activating 5-HT4 receptors.22 Moreover, a positive dechallenge was reported in six cases from VigiBase, and a positive rechallenge was noted in one of the published cases,25 further supporting the experimental evidence in favor of the causal relationship.There are multiple experimental evidences indicative of the association.8CoherenceThere are multiple case studies on this association, and metoclopramide is labeled as contraindicated in pheochromocytoma patients in several SmPCs1–3 from various regulatory bodies. This is further supported by several small-scale experimental studies25,29,31 and proposed biological mechanisms.22,31,42The association is coherent with establishedknowledge.9AnalogyOther dopamine antagonists and/or serotonin agonists, including droperidol,14 amisulpride and tiapride,13 and cisapride22 have been associated with pheochromocytoma crisis or catecholamine secretion.Analogies with other drugs explain a similar association.Abbreviations: IC, Information component; PTs, Preferred Terms; PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio. Table 3Summary of Evidence: Hill’s Criteria for Causality AssessmentCriteriaSummary of EvidenceInterpretation1Strength of associationIn the global pharmacovigilance database, VigiBase, a robust statistical signal was observed for this association. For pheochromocytoma crisis specifically, an Information Component (IC025) value of 4.5, a Proportional Reporting Ratio (PRR025) of 82.4, and a Reporting Odds Ratio (ROR025) of 127.0 were reported.There is a strong statistical association between metoclopramide and pheochromocytoma crisis.2Consistency of the casesCases reported to VigiBase originated from 11 countries across five continents. Furthermore, 11 of the published cases showed reaction onset of immediate or within a few minutes, contributing to the consistency of the observed association.The association between metoclopramide and pheochromocytoma crisis demonstrates consistency across various reports.3Specificity of the associationMetoclopramide was identified as the sole suspected drug in 46 of all the cases, with 29 of them (10 published cases and 19 from VigiBase) involving metoclopramide as the only administered medication. In all (18) published cases, there was a clear diagnosis of pheochromocytoma crisis/hypertensive crisis and the underlying condition of pheochromocytoma. Additionally, no alternative causes were identified in 13 of the published cases, and in five of these, other alternatives were specifically ruled out (Table 2).The association appears specific in terms of the exposure and outcome of interest.4TemporalityIn all (n=62) of the cases pheochromocytoma crisis occurred following metoclopramide administration. Specifically, a plausible temporal relationship exists, as pheochromocytoma crisis developed immediately within a few minutes following metoclopramide administration in almost all the published cases.There is a plausible temporal relationship.5Dose-responserelationship/ biological gradientExperimental study has shown that administering graded concentrations of metoclopramide to pheochromocytoma cells induced a dose-dependent increase in norepinephrine and epinephrine secretion.22Evidence suggests a plausible dose-response relationship6Biological mechanism orPlausibilityResearches indicate that metoclopramide may induce catecholamine release through dopamine D2 receptor inhibition5,25 and/or activation of serotonin 5-HT4 receptors.22 Metoclopramide is also suggested to stimulate the release of biologically active vasopressin in humans.42There are proposed biological mechanisms suggestive of this association.7ExperimentTwo cases, in which metoclopramide was used as provocation test,25,29 confirmed the crisis onset within 2–3 minutes following IV administration and no effects were noted when metoclopramide was readministered after tumor removal.25 There was also no change in blood pressure or plasma catecholamine levels in six other individuals used as controls in these two studies.25,29 Another study by Kawabe et al reported a significant pressor response to intravenous metoclopramide only in patients with pheochromocytoma, whereas patients with essential hypertension and normotensive subjects showed mild depressor responses.31 Metoclopramide has also been shown to increase catecholamine release from isolated human pheochromocytomas but not from isolated rat adrenal glands used as control tissue.40 Tissue explants from pheochromocytomas demonstrated metoclopramide’s stimulating effect on catecholamine release by activating 5-HT4 receptors.22 Moreover, a positive dechallenge was reported in six cases from VigiBase, and a positive rechallenge was noted in one of the published cases,25 further supporting the experimental evidence in favor of the causal relationship.There are multiple experimental evidences indicative of the association.8CoherenceThere are multiple case studies on this association, and metoclopramide is labeled as contraindicated in pheochromocytoma patients in several SmPCs1–3 from various regulatory bodies. This is further supported by several small-scale experimental studies25,29,31 and proposed biological mechanisms.22,31,42The association is coherent with establishedknowledge.9AnalogyOther dopamine antagonists and/or serotonin agonists, including droperidol,14 amisulpride and tiapride,13 and cisapride22 have been associated with pheochromocytoma crisis or catecholamine secretion.Analogies with other drugs explain a similar association.Abbreviations: IC, Information component; PTs, Preferred Terms; PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio. Summary of Evidence: Hill’s Criteria for Causality Assessment Abbreviations: IC, Information component; PTs, Preferred Terms; PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio. Discussion This comprehensive causality assessment that integrated evidence from both the WHO global pharmacovigilance database (VigiBase) and published medical literature revealed compelling evidence of a causal relationship between metoclopramide and pheochromocytoma crisis across all nine Hill’s criteria39 and the Naranjo probability scale.38 Based on the individual-level causality assessment, most cases were classified as probable, supporting a clinically meaningful association between metoclopramide exposure and pheochromocytoma crisis. The absence of definite cases is expected given the incomplete information due to the retrospective nature of the data, ethical constraints precluding rechallenge information, and the frequent need for urgent pharmacological or surgical intervention in this life-threatening condition, which limits dechallenge assessment and precludes attribution solely to metoclopramide withdrawal or dose reduction. In most of the cases withdrawal of metoclopramide was conducted in parallel to the pharmacological and surgical management of the crisis resulting an unknown dechallenge information. Moreover, missing information for several Naranjo items, including the dose-response relationship, placebo challenge, and drug concentration measurements, may have compromised the scoring. These factors inherently limit the maximum achievable score and are likely to result in underestimation of individual-level causality. Overall, these findings highlight the limitations of algorithm-based tools in retrospective analyses of rare and severe adverse drug reactions and underscore the importance of interpreting individual-case assessments alongside population-level causality frameworks. When integrated with the consistent evidence observed across the Austin Bradford Hill criteria, the individual-level results contributed to a robust overall inference of a causal relationship between metoclopramide and pheochromocytoma crisis, providing strong signal verification for this association. According to Hill’s criteria analysis, the strength of the association is supported by quantitative data from VigiBase, where a robust statistical signal was observed for the drug-adverse reaction pair. In the global pharmacovigilance database, cases of pheochromocytoma crises following the use of metoclopramide were reported to be significantly higher than expected, as demonstrated by IC025 values of greater than 0 and PRR025 and ROR025 values of greater than 1.35–37 In addition, a temporal relationship was evident, with most cases demonstrating a rapid onset of symptoms within minutes of drug administration. The onset of the pharmacological action of metoclopramide is generally expected to be 1–3 min after intravenous administration, 10–15 min after intramuscular administration, and 30–60 min after an oral dose.1–3 The rapid onset of crisis in 11 cases, including those from controlled experimental studies,25,28,29 was consistent with the known pharmacokinetic profile of metoclopramide, suggesting a plausible temporal relationship. The association also exhibited consistency, with multiple cases reported from various geographical locations (VigiBase data) in a consistent reaction onset pattern, supporting a causal link. In a substantial proportion of cases, metoclopramide was the only suspected drug, and in several patients, it was the only medication administered. In addition, several cases reported no alternative causes and explicitly ruled out alternatives, supporting the specificity of the association. The specificity of this association was further emphasized by the clear diagnosis and characterization of pheochromocytoma crisis in almost all published case reports through clinical, imaging, laboratory assessments, and postsurgical histopathology. Several studies have proposed multiple biological mechanisms and described a dose–response relationship between metoclopramide and pheochromocytoma crisis, thereby fulfilling Hill’s criteria. One study suggested that the high endogenous catecholamines found in tumor tissues were the reason for the pheochromocytoma crisis.40 Another study suggested that metoclopramide stimulates the release of biologically active vasopressin in humans.42 Furthermore, stimulation of dopamine D2 receptors on presynaptic nerve endings that inhibit catecholamine release and ganglion transmission has been suggested as the mechanism for increased catecholamines and blood pressure.15,25 However, another in vitro experimental study22 which investigated the mechanism of action of metoclopramide and the expression of serotonin type 4 (5-HT4) receptors in pheochromocytoma tissues demonstrated that metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma tissue by activating serotonin 5-HT4 receptors independent of D2 receptor antagonism. This study confirmed the mechanism by incubating cultured pheochromocytoma cells with cisapride and domperidone. Cisapride, a 5-HT4 receptor agonist devoid of any antidopaminergic properties, significantly stimulated catecholamine and granin-derived peptide release. In contrast to cisapride, domperidone—a dopaminergic D2 receptor antagonist that lacks agonistic activity at the 5-HT4 receptor—had no significant effect on catecholamine- or granin-derived peptide release. In addition, a dose–response relationship between metoclopramide and pheochromocytoma crisis is reported in this in vitro experimental study.22 Accordingly, the administration of graded concentrations of metoclopramide (10-9–10-6M) to pheochromocytoma cells in primary culture induced a dose-dependent increase in norepinephrine and epinephrine secretions. Published22,25,29,31,40 and unpublished data (reports from VigiBase) support the existence of experimental evidence of the association between metoclopramide and pheochromocytoma crisis. Experimental studies that included a few patients with pheochromocytoma and those without pheochromocytoma as control groups reported hypertensive crisis and increased catecholamines in pheochromocytoma patients, whereas no such effects were observed in cases without pheochromocytoma.29,31,40 The tissue explants from pheochromocytomas, which demonstrated metoclopramide’s stimulation of catecholamine release from pheochromocytoma cells22,40 corroborate experimental evidence supporting the causal link. One of these studies reported increased catecholamine release from four isolated human pheochromocytomas, but not from isolated rat adrenal glands used as controls.40 There were also a few cases (reported to VigiBase) with positive dechallenge and one case with positive rechallenge, further supporting experimental evidence in favor of the causal relationship. Furthermore, the absence of pheochromocytoma crisis when metoclopramide was administered following adrenalectomy in one case;25 a significant pressor response to intravenous metoclopramide in patients with pheochromocytoma in contrast to the subjects with essential hypertension and normotension;31 and the absence of changes in blood pressure or plasma catecholamine levels in six other individuals used as controls when compared to those with pheochromocytoma25,29 indicates positive experimental evidence supporting the causal inference. This association is coherent with established medical knowledge and supported by the analogous pharmacological effects of related agents, satisfying both the coherence and analogy criteria. Coherence is underscored by consensus among several regulatory bodies that have contraindicated metoclopramide in patients with known or suspected pheochromocytoma, thereby integrating this association into the existing medical guidelines. Further support is provided by both experimental studies and the proposed biological mechanisms, which elucidate a plausible link between the drug and the adverse event.22,31 Similar pharmacological agents (other dopamine antagonists), such as amisulpride and tiapride,13 and droperidol,14 have also been documented to precipitate a pheochromocytoma crisis, satisfying the analogy criterion. Moreover, the activation of catecholamine secretion from the patient’s tumor cells by cisapride, a 5-HT4 receptor agonist similar to metoclopramide,22 also supports the analogy of this association. The findings of this study have important clinical practice and public health implications. The contraindication of metoclopramide in patients with known or suspected pheochromocytoma should be strongly reinforced. Healthcare providers should maintain a high index of suspicion for underlying pheochromocytoma in patients receiving metoclopramide who present with symptoms suggestive of a catecholamine surge, such as severe headache or refractory hypertension. Enhanced education on this drug–disease interaction is essential for safe clinical practice. In addition, caution may be warranted with other dopamine antagonists and/or serotonin agonists, given the proposed mechanisms of action15,22,25 and reported cases of similar drug-associated crises.13,14,22 Although the included case reports provided detailed documentation and clear diagnosis of pheochromocytoma crisis, several limitations should be acknowledged. Causal inference from VigiBase data is limited by reporting biases, incomplete clinical information, absence of denominators, and potential residual confounding. In most cases, rechallenge and dechallenge information was unavailable due to the acute and life-threatening nature of the condition which required aggressive management of the crisis. This could cause a significant limitation in causality assessment, which could shift the causal relationship towards a weaker category. Additionally, alternative causes of catecholamine surge, such as trauma, vigorous exercise, or tumor necrosis, may not have been completely ruled out9,10 in some cases. Finally, the low background risk of pheochromocytoma makes it difficult to conduct large-scale controlled studies, necessitating causal inferences based on spontaneous reports, case series, and experimental studies with a few cases. Conclusion This comprehensive causality assessment showed fulfilment of the Austin Bradford Hill criteria at the population level and supportive individual-level assessments, indicating a reasonable causal relationship. These findings critically reinforce the established contraindications for metoclopramide in patients with known or suspected pheochromocytoma. Although this study provides strong signal verification, future international collaborative epidemiological studies, such as case-control studies, are recommended to further substantiate the causal association between this rare but critical adverse drug reaction and metoclopramide.